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RESEARCH ARTICLE
Hyperactivity and attention deficits inmicewith decreased levels of
stress-inducible phosphoprotein 1 (STIP1)
Flavio H. Beraldo1,*, Anu Thomas1, Benjamin Kolisnyk1,2, Pedro H. Hirata1, Xavier De Jaeger1,
Amanda C. Martyn1, Jue Fan1, Daniela F. Goncalves1, Matthew F. Cowan1, Talal Masood1,2,
Vilma R. Martins3, Robert Gros1,4, Vania F. Prado1,2,4,5,* and Marco A. M. Prado1,2,4,5,*
ABSTRACT
Stress-inducible phosphoprotein I (STIP1, STI1 or HOP) is a co-
chaperone intermediating Hsp70/Hsp90 exchange of client proteins,
but it can also be secreted to trigger prion protein-mediated neuronal
signaling. Some mothers of children with autism spectrum disorders
(ASD) present antibodies against certain brain proteins, including
antibodies against STIP1. Maternal antibodies can cross the fetus
blood-brain barrier during pregnancy, suggesting the possibility that
they can interfere with STIP1 levels and, presumably, functions.
However, it is currently unknown whether abnormal levels of STIP1
have any impact in ASD-related behavior. Here, we used mice with
reduced (50%) or increased STIP1 levels (fivefold) to test for potential
ASD-like phenotypes. We found that increased STIP1 regulates the
abundance of Hsp70 and Hsp90, whereas reduced STIP1 does not
affect Hsp70, Hsp90 or the prion protein. Interestingly, BAC
transgenic mice presenting fivefold more STIP1 show no major
phenotype when examined in a series of behavioral tasks, including
locomotor activity, elevated plus maze, Morris water maze and five-
choice serial reaction time task (5-CSRTT). In contrast, mice with
reduced STIP1 levels are hyperactive and have attentional deficits on
the 5-CSRTT, but exhibit normal performance for the other tasks. We
conclude that reduced STIP1 levels can contribute to phenotypes
related to ASD. However, future experiments are needed to define
whether it is decreased chaperone capacity or impaired prion protein
signaling that contributes to these phenotypes.
KEY WORDS: Touchscreen, Autism, ASD, Stress-inducible
phosphoprotein 1, Attention deficits, Mouse model, BAC
INTRODUCTION
In autism spectrum disorders (ASD), alterations in genetic variance
and neurodevelopmental are both thought to contribute to
phenotype heterogeneity. Womb environment and autoimmune
responses have been proposed to contribute to the complex
behavioral alterations observed in ASD, which include, but are
not limited to, abnormal socialization and communication and
stereotyped behavior (Brimberg et al., 2013; Goldani et al., 2014).
Several distinct groups have investigated the existence of antibodies
against fetal brain tissue in mothers of ASD children (Bauman et al.,
2013; Braunschweig et al., 2012b, 2013; Dalton et al., 2003;
Nordahl et al., 2013). Passive transfer of maternal anti-brain
antibodies to pregnant experimental animal models (including mice,
rats and non-human primates) has shown that their offspring
develop a number of endophenotypes that resemble phenotypes in
ASD (Bauman et al., 2013; Braunschweig et al., 2012b; Dalton
et al., 2003). Indeed, a recent study indicated that the prevalence of
antibodies against fetal brain proteins is increased fourfold in
mothers of an ASD child compared with control groups (Brimberg
et al., 2013). Proteomics analysis has identified six brain proteins as
targets for ASD antibodies, including lactate dehydrogenase A and
B (LDH), cypin, stress-inducible phosphoprotein protein1 (STIP1),
collapsine response mediator proteins 1 and 2 (CRMP1, CRMP2)
and Y-box-binding protein (YBX1) (Braunschweig et al., 2013).
Interestingly, injection of maternal antibodies that recognize LDH,
STIP1 and CRMP1 in developing mouse embryos causes an
increase in cortical neural precursor proliferation and cortical
neuron volume, with consequent increase in brain size and weight
(Martinez-Cerdeno et al., 2014). These phenotypes are consistent
with the notion that the presence of maternal autoantibodies can
affect neuronal development.
STIP1, also known as heat-shock organizing protein (Hop) or
STI1, is a co-chaperone that interacts concomitantly with heat-
shock proteins 70 and 90 (Hsp70 and HsP90) (Abbas-Terki et al.,
2002; Chen et al., 1996; Nicolet and Craig, 1989; Picard, 2002;
Smith et al., 1993). The chaperone machinery is thought to provide a
buffer for cells to respond to environmental challenges; disturbance
of Hsp70/90 chaperone activity decreases cellular resilience to
stress (Chen et al., 2015; Hashimoto-Torii et al., 2014; Taipale et al.,
2010, 2014). The absence of STIP1 in mice has important
consequences for development, including increased apoptosis,
DNA damage and death (Beraldo et al., 2013). These phenotypes
are rescued by transgenic BAC expression of STIP1 (Beraldo et al.,
2013).
In addition to its intracellular role as a co-chaperone, STIP1 is also
secreted by a variety of cells (Erlich et al., 2007; Eustace and Jay,
2004; Hajj et al., 2013; Lima et al., 2007; Wang et al., 2010) via
extracellular vesicles (Hajj et al., 2013). Extracellular STIP1 can
signal via the prion protein (PrPC) to produce a myriad of effects
related to brain development (Beraldo et al., 2010, 2013; Caetano
et al., 2008; Lopes et al., 2005; Soares et al., 2013). Here, we used
Stip1 heterozygous mice (STI1−/+ mice), as well as mice
overexpresssing four- to fivefold more STIP1 (STI1TGA mice), to
investigate the consequences of alteration of STIP1 levels in vivo.Received 30 July 2015; Accepted 4 September 2015
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We report that decreased, but not increased, STIP1 levels affect
attention and cause hyperactivity in mice, two phenotypes that are
related to ASD-like phenotypes. Our results suggest that interference
with STIP1 functions, which presumably occur in the presence of
STIP1 antibodies, has the potential to contribute to ASD-like
phenotypes.
RESULTS
We initially confirmed previous data to show that STI1−/+ mice
present 50% of STIP1mRNA levels in their brain, whereas STI1TGA
mice express almost sixfold more mRNA (Fig. 1A; one-way
ANOVA; revealed main effect of genotype F(2.15)=8.521,
P<0.0001). In contrast, mRNA levels of known STIP1 interaction
partners PrPC (Fig. 1B; one-way ANOVA F(2.16)=1.475, P=0.2580),
Hsp70 (Fig. 1C; one-way ANOVA F(2.16)=0.301, P=0.744)
and Hsp90 (Fig. 1D; one-way ANOVA F(2.8)=1.249, P=0.337)
were not altered in the brain of the two lines, compared with
control mice.
Protein levels for STIP1 followed mRNA levels for both STI1TGA
(Fig. 2A; t(15)=4.721, P=0.003) and STI1
−/+ (Fig. 2B; t(14)=6.433,
P<0.0001). PrPC protein levels were not different from controls in
both lines (Fig. 2C,D; t(10)=1.049, P=0.391 and t(13)=1.128,
P=0.279, respectively). Interestingly, levels of Hsp70 were
decreased by 50% in STI1TGA brains (Fig. 2E; t(7)=5.846,
P=0.0006), whereas no change in Hsp70 levels was detected in
STI1−/+ mice (Fig. 2F; t(7)=0.123, P=0.9051), compared with
controls. Additionally, Hsp90 levels detected with a pan Hsp90
antibody were doubled in STI1TGA brains (Fig. 2G; t(22)=4.618,
P=0.0001) but not changed in STI1−/+ brains (Fig. 2H; t(10)=0.308,
P=0.7639), compared with controls. We then evaluated expression
levels of Hsp90α (inducible form) and Hsp90β (constitutive form)
in the brains of STI1TGA mice and observed that both forms were
significantly increased (Fig. 2I,J; t(22)=4.618, P=0.0016 and
t(16)=5.954, P<0.0001, respectively).
Spontaneous locomotor activity in a new environment can
provide information on neuropsychiatric phenotypes in mice
associated with genetic mutations. The increased number of Stip1
copies, with concomitant overexpression of Hsp90 and decreased
expression of Hsp70 in STI1TGA mice did not seem to have any
major impact on spontaneous locomotion (Fig. 3A,B; t(29)=1.140,
P=0.942) or time spent in the center of the box, which provides
insight on anxiety-like behavior (Fig. 3C; t(29)=1.236, P=0.8669).
In contrast, locomotor activity and total locomotion in a new
environment were increased in STI1−/+ mice (Fig. 3D,E;
t(44)=1.879, P=0.0078). However, STI1
−/+ mice did not show
increased anxiety-like behavior, as determined by the time spent in
the center of the box (Fig. 3F; t(40)=1.221, P=0.341). We also
examined another cohort of STI1−/+ mice using automated
metabolic cages. In this experiment, which mimics the home cage
environment, STI1−/+ mice again showed hyperactivity during the
day and night periods, considering both total activity (Fig. 3G;
t(14)=2.558, P=0.0228 and t(14)=2.230, P=0.0426) and ambulatory
activity (Fig. 3H; t(14)=2.420, P=0.00297 and t(14)=2.230,
P=0.0426). Given this increased motor activity, STI1−/+ mice also
demonstrated less sleep time (periods of inactivity) (Fig. 3I;
t(14)=3949, P=0.0015 and t(14)=2.724, P=0.0165). Also, STI1
−/+
mice showed increased consumption of O2 during the light and dark
cycle (Fig. 3J; t(14)=2.464, P=0.027 and t(14)=2.169, P=0.047) and
CO2 production during the dark cycle, but not in the light cycle
(Fig. 3K; t(14)=2.307, P=0.036 and t(14)=1.360, P=0.195). No
differences were observed in other parameters such as respiratory
ratio (Fig. 3L; t(14)=0.4455, P=0.6627 and t(14)=0.459, P=0.653),
food consumption (Fig. 3M; t(14)=0.5216, P=0.6101 and
t(14)=0.6134, P=0.5494), water consumption (Fig. 3N;
t(14)=1.801, P=0.0933 and t(14)=0.2752, P=0.7872), and heat
production (Fig. 3O; t(14)=1.014, P=0.3276 and t(14)=0.1935,
P=0.8494) comparing STI1−/+ to STI1+/+ mice for both cycles
(light and dark).
In order to test for other neuropsychiatric-like behaviors as a result
of altered STIP1 levels we tested both STITGA and STI1−/+ mice for
anxiety-like behavior (Fig. 4A-D) and depression-like behavior
(Fig. 4E,F). Given the hyperactivity of STI1−/+ mice, we also
decided to investigate whether they had alterations in compulsive-
like behavior, assessed by measurement of self-grooming and
marble burying (Fig. 4G-I). There was no difference in the behavior
of either STITGA (Fig. 4A,B,E) or STI1−/+ (Fig. 4C,D,F-I) mice
compared with control mice in all these behavioral tasks: time spent
in the open arm (Fig. 4C; t19=0.310, P=0.7590), time spent in the
closed arm (Fig. 4D; t(19)=0.3730, P=0.7133), forced swim test
(Fig. 4F; t(12)=1.184, P=0.2594), grooming bouts (Fig. 4H;
t(20)=0.7848, P=0.4418), time grooming (Fig. 4G; t(20)=0.6072,
P=0.5505) and marble burying (Fig. 4I; t(21)=0.4956, P=0.6253).
TRANSLATIONAL IMPACT
Clinical issue
Autism spectrum disorders (ASD) represent a range of
neurodevelopmental disorders with no cure. ASD is characterized by
difficulties in communication and socialization, repetitive movements,
hyperactivity, impulsivity, and an impaired ability to concentrate and
attend to simple tasks. Genetic variance and neurodevelopmental
alterations are both thought to contribute to the heterogeneity of the ASD
phenotype. Recent studies have demonstrated that some mothers of
children with ASD produce antibodies against six specific proteins
present in the fetal brain; presumably, these antibodies can interfere with
protein function in the developing brain. One of these antibodies targets a
protein known as stress inducible phosphoprotein 1 (STIP1). Moreover, a
polymorphism for STIP1 was recently identified as a potential risk factor
in attention deficit hyperactivity disorder, which shares some phenotypes
with ASD. STIP1 is a co-chaperone that mediates the Hsp70/Hsp90
exchange of client proteins. It also triggers prion protein-mediated
neuronal signaling.
Results
Here, to investigate the potential involvement of STIP1 in ASD, the
authors examinemice that express reduced (50%) or increased (fivefold)
levels of STIP1. They show that increased STIP1 levels regulate the
abundance of Hsp70 and Hsp90. By contrast, reduced STIP1 levels
have no effect on Hsp70, Hsp90 or prion protein levels. Notably,
however, mice expressing increased levels of STIP1 show no major
phenotype when examined using a range of behavioral tasks, whereas
mice expressing reduced levels of STIP1 exhibit attention deficits and
are hyperactive.
Implications and future directions
Because attention deficits and hyperactivity are present in ASD, these
findings suggest that interference with STIP1 functions (but not
increased STIP1 levels) can contribute to ASD-like phenotypes.
Changes in STIP1 levels, possibly triggered by the presence of
maternal anti-STIP1 antibodies during brain development, might
interfere with the development of brain circuits that affect ASD-like
behavior. Additional experiments are required to determine whether
decreased STIP1 contributes to ASD-like phenotypes by decreasing
chaperone capacity in the developing brain, by impairing prion protein
signaling, or through some other mechanism, and to define fully the
consequences of disturbed STIP1 activity in ASD.
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Next, we investigated spatial navigation memory in both Stip1
mutant mice using the Morris water maze (MWM). Neither
STI1TGA nor STI1−/+ mice presented deficits in acquisition
or retrieval of spatial memory in the MWM. For both STI1TGA
and STI1−/+, performance during the 4-day acquisition phase was
indistinguishable from their wild-type controls in terms of latency to
find the target (Fig. 5A; RM-ANOVA F(1,13)=0.062, P=0.806) or
speed (Fig. 5C; F(1,10)=0.215, P=0.652). When spatial memory
retrieval was performed on the day-5 probe trial, again no
differences were observed between STI1TGA and STI1−/+ mice,
compared with their wild-type controls, for time spent investigating
the target quadrant (Fig. 5D; F(1,13)=1.046, P=0.3251) or latency
(Fig. 5E; F(1,10)=0.215, P=0.294).
Given the hyperactivity phenotype and genetic data suggesting
the potential of STIP1 to be linked to ADHD (Mick et al., 2011), a
trait commonly found in ASD (Gadow et al., 2006; Goldstein and
Schwebach, 2004; Lee and Ousley, 2006; Mulligan et al., 2009), we
also determined whether changes in STIP1 levels affected
attentional processing. For this, we used the 5-CSRTT. After mice
were trained to perform to a criterion (>80% accuracy, <20%
omissions) at a 2 s stimulus duration, we assessed attentional
performance by using reduced stimulus durations in probe trials
(1.5, 1, 0.8 and 0.6 s stimulus durations) as previously described
(Romberg et al., 2011). We observed no differences in attentional
performance in STI1TGA mice compared with their littermate
controls. There was no difference in accuracy (Fig. 6A; RM-
ANOVA showed no effect of genotype F(1,20)=0.0057, P=0.9403,
main effect of stimulus duration F(3,60)=12.14, P<0.0001 and no
significant interaction F(3,60)=0.1328, P=0.9402) or omission rates
(Fig. 6B; RM-ANOVA showed no effect of genotype
F(1,18)=0.2429, P=0.6281, main effect of stimulus duration
F(3,54)=17.62, P<0.0001 and significant interaction F(3,54)=3.854,
P=0.0143). Post-hoc analysis showed that there was no significant
difference between STI1TGA mice and controls. There was also no
difference in premature responses, a measure of impulsivity
(Fig. 6C; RM-ANOVA showed no effect of genotype
F(1,9)=0.00056, P=0.9419, no effect of stimulus duration
F(3.27)=0.8254, P=0.4914 and no significant interaction
F(3,27)=1.109, P=0.3625). Moreover, we did not find any
difference in motivation, measured as latency to touch the screen
(Fig. 6D; RM-ANOVA showed no effect of genotype F(1,9)=3.399,
P=0.0983, main effect of stimulus duration F(3.30)=4.281, P=0.0125
and no significant interaction F(3,30)=2.332, P=0.0941).
Compulsivity and motivation were not altered either, as assessed
by perseverative responses (Fig. 6F; RM-ANOVA, showed no
effect of genotype F(1,9)=3.974, P=0.0774, main effect of stimulus
duration F(3,27)=4.808, P=0.0083 and no significant interaction
F(3,27)=0.1773, P=0.9108) and reward collection latency (Fig. 6E;
RM-ANOVA showed no effect of genotype F(1,10)=1.291,
P=0.2824, no effect of stimulus duration F(3,30)=2.162, P=0.1132
and no significant interaction F(3.30)=0.7372, P=0.5381).
In contrast, when attentional demand was increased, STI1−/+
mice presented decreased accuracy (Fig. 6G; RM-ANOVA, main
effect of genotype F(1,25)=6.872, P=0.0147, main effect of stimulus
duration F(3,75)=41.95, P<0.0001, significant interaction effect
F(3,75)=4.170, P=0.0087) and increased omission rates (Fig. 6H;
RM-ANOVA, main effect of genotype F(1,25)=6.584, P=0.0167,
main effect of stimulus duration F(3,75)=24.62, P<0.0001,
significant interaction effect F(3,75)=3.401, P=0.0220). Post-hoc
analysis revealed that the STI1−/+ mice were significantly impaired
in both accuracy and omissions at the 0.6 s stimulus duration. The
worse performance of STI1−/+ mice was not related to changes in
motivation (latency to respond to the stimulus, RM-ANOVA, no
effect of genotype F(1,25)=0.01856, P=0.8925, no effect of stimulus
duration F(3,75)=1.720, P=0.1702, no interaction F(3,75)=1.070,
P=0.3669). There was also no difference in latency to retrieve the
reward following a correct response (RM-ANOVA, no effect of
genotype F(1,25)=0.03176, P=0.8600, no effect of stimulus duration
F(3,75)=0.3997, P=0.7536, no interaction F(3,75)=1.785, P=0.8284).
Moreover, we detected no increase in premature responses (RM-
ANOVA, no effect of genotype F(1,25)=0.0958, P=0.7595, main
effect of stimulus duration F(3,75)=2.907, P=0.0401, no interaction
effect F(3,75)=2.017, P=0.1187) or perseverative responses (RM-
ANOVA, no effect of genotype F(1,25)=0.04188, P=0.8395, main
effect of stimulus duration F(3,75)=6.975, P=0.0003, no interaction
effect F(3,75)=1.139, P=0.3389).
Fig. 1. Analyses of mRNA for STIP1
partners in STI1+/+, STI1−/+ and STI1TGA
mouse brains. (A) STIP1 mRNA
expression (n=9 STI1+/+, n=5 STI1TGA and
n=4 STI1−/+). (B) PrPC mRNA expression
(n=8STI1+/+,n=4STI1TGAandn=7STI1−/+).
(C) Hsp70mRNA expression (n=8 STI1+/+,
n=4 STI1TGA and n=7 STI1−/+). (D) Hsp90
mRNA expression (n=3 STI1+/+, n=4
STI1TGA and n=4 STI1−/+). Results are
presented as means±s.e.m.; data were
analyzed and compared byone-wayANOVA
and Bonferroni multiple comparisons
post-hoc test; **P<0.001 and ***P<0.0001
compared with control.
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DISCUSSION
The present experiments tested whether alterations in STIP1 levels
have consequences for psychiatric-like behaviors in mice. Our
results suggest that decreased, but not increased, STIP1 levels cause
significant behavioral alterations in mice. Spatial learning and
memory, as well as anxiety and depression-like behavior do not
seem to be affected by reduced STIP1 levels. However, mutant mice
deficient for STIP1 are hyperactive and present attention deficits.
STIP1 has recently emerged as a protein of potential interest in
ASD and endophenotypes related to ASD. Maternal autoantibodies
against STIP1 have been identified in mothers of children with ASD
(Braunschweig et al., 2013). Moreover, recent global-wide
association study (GWAS) analysis identified a polymorphism in
STIP1 (the human gene coding for STIP1/HOP) as a potential risk
factor in a population of individuals diagnosed with attention-deficit
disorder (Mick et al., 2011), a co-morbidity often associated with
ASD (Brimberg et al., 2013; Goldani et al., 2014). The consequences
of this polymorphism for STIP1 expression is unknown, but the
presence of autoantibodies against STIP1 might affect expression
levels of the protein, given that antibodies can penetrate the blood
brain barrier of the fetus during pregnancy (Braunschweig et al.,
2012a; Diamond et al., 2009; Fox et al., 2012; Zhang et al., 2012).
Indeed, maternal antibodies that recognize STIP1 and other targets
when injected in pregnant rodents or developing pups can lead to
offspring with abnormal neurons and behaviors that relate to ASD
(Braunschweig et al., 2012b; Camacho et al., 2014). To a degree,
STI1−/+ mice model this early developmental deficit in STIP1 levels.
However, in STI1−/+ mice STIP1 expression is persistently decreased
through life, which could also have important consequences for the
phenotypes described.
STIP1 is a modular protein containing several tetratricopeptide
(TRP) repeat domains and aspartate-proline (DP) reach domains
(Taipale et al., 2010). TRP1 and TRP2B can interact with Hsp70
(Flom et al., 2007; Scheufler et al., 2000), whereas TPR2A is required
for interactionwithHsp90 (Flom et al., 2007, 2006). Hsp90 activity is
regulated by STIP1 and previous work has shown that in mice no
other co-chaperone can replace STIP1 (Beraldo et al., 2013). Recent
experiments have indicated that the chaperone machinery, activated
by the transcription factor heat shock factor 1 (HSF1), is responsible
for preventing damaging effects from environmental factors in the
developing brain (Hashimoto-Torii et al., 2014). Indeed, the
chaperone machinery can buffer many stresses at the cellular level
and, therefore, it is not surprising that functional changes in its
components have physiological consequences.
In addition to its intracellular chaperone function, STIP1 is also
secreted by a myriad of cells, including astrocytes via an
extracellular vesicle population, which includes exosomes (Hajj
et al., 2013). Extracellular STIP1 also mediates important
physiological responses in the brain. Acting as a trophic factor to
engage PrPC to signal in neurons, it regulates neuritogenesis and
Fig. 2. Analyses of protein levels for STIP1 partners in STI1+/+, STI−/+ and STI1TGAmouse brains. (A,B) STIP1 expression in STI1TGA (n=9 STI1+/+ and n=8
STI1TGA) and STI1−/+ mice (n=8 STI1+/+ and n=8 STI1−/+). (C,D) PrPC expression in STI1TGA (n=6 STI1+/+ and n=6 STI1TGA) and STI1−/+ mice (n=6 STI1+/+
and n=9 STI1−/+). (E,F) Hsp70 expression in STI1TGA (n=5 STI1+/+ and n=4 STI1TGA) and STI1−/+ mice (n=5 STI1+/+ and n=4 STI1−/+). (G,H) HSP90 expression
in STI1TGA (n=10 STI1+/+ and n=14 STI1TGA) and STI1−/+ mice (n=6 STI1+/+ and n=6 STI1−/+). (I,J) Hsp90β (n=10 STI1+/+ and n=8 STI1TGA) and Hsp90α (n=5
STI1+/+ and n=4 STI1TGA) in STI1TGA mice. Results are presented as means±s.e.m.; data were analyzed and compared by Student’s t-test; *P<0.05 and
***P<0.0001 compared with control.
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neuronal survival (Beraldo et al., 2010; Lopes et al., 2005; Roffe
et al., 2010). STIP1 has a role in functional recovery in stroke
(Beraldo et al., 2013; Lee et al., 2013). Moreover, STIP1 also
modulates toxicity of Aβ peptides in models of Alzheimer’s disease
(Brehme et al., 2014; Ostapchenko et al., 2013).
It is remarkable that mice with increased levels of STIP1 (up to
almost fivefold) do not present any major behavioral alteration. In
the extensive evaluation of cognitive phenotypes in this study,
which included anxiety and depression-like behaviors, spatial
memory and attention, we showed that STI1TGA mice perform as
well as littermate controls. These results suggest that strategies to
increase STIP1 levels should not cause toxicity with consequences
for brain functions. This is important, given that increased STIP1
levels might be protective against insults such as stroke-mediated
Fig. 3. Locomotor activity in STI1TGA and STI1−/+mice andmetabolic analyses in STI1−/+mice. (A) Horizontal locomotor activity in an open-field for STI1TGA
(n=14) and STI+/+ control mice (n=14). (B) Cumulative 1 h locomotion for STI1TGA (n=14) and STI+/+ control mice (n=14). (C) Time spent in the center of the
locomotion boxes for STI1TGA (n=14) and STI+/+ control mice (n=14). (D) Horizontal locomotor activity in an open-field for STI1−/+ (n=8) and STI+/+ control mice
(n=8). (E) Cumulative 1 h locomotion for STI1−/+ (n=22) and STI+/+ control mice (n=24). (F) Time spent in the center of the locomotion boxes for STI1−/+ (n=22)
and STI+/+ control mice (n=24). (G) Total activity in metabolic cages for STI1−/+ (n=8) and STI+/+ control mice (n=8). (H) Ambulatory activity in metabolic cages
for STI1−/+ (n=8) and STI+/+ control mice (n=8). (I) Sleep time for STI1−/+ (n=8) and STI+/+ control mice (n=8). (J) VO2 for STI1
−/+ (n=8) and STI+/+ control mice
(n=8). (K) VCO2 for STI1
−/+ (n=8) and STI+/+ control mice (n=8). (L) Respiratory exchange ratio for STI1−/+ (n=8) and STI+/+ control mice (n=8). (M) Food
consumption for STI1−/+ (n=8) and STI+/+ control mice (n=8). (N) Water consumption for STI1−/+ (n=8) and STI+/+ control mice (n=8). (O) Energy expenditure for
STI1−/+ (n=8) and STI+/+ control mice (n=8). Results are presented as means±s.e.m.; data were analyzed and compared by Student’s t-test; *P<0.05 compared
with control.
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cell death and in Alzheimer’s disease (Beraldo et al., 2013;
Ostapchenko et al., 2013). Interestingly, whereas increased levels of
STIP1 seem to affect the chaperone machinery, prion protein
expression is not affected by decreasing the level of Hsp70 and
increasing Hsp90. These consequences of increased STIP1 seem to
occur at the post-translational level, given that mRNAs for Hsp70
and 90 were not affected. It is unknown at the moment whether
increased STIP1 levels stabilize a complex containing Hsp90,
preferentially leading to increased turnover of Hsp70.
At present, the exact mechanism by which decreased STIP1 levels
affect psychiatric-like behavior is still unknown. Although it is
possible that decreased levels of STIP1 during early development
have persistent effects in brain circuits, culminatingwith hyperactivity
and attentional deficits, we cannot discard the possibility that
STIP1 plays a role in regulating circuitry function in the adult brain.
Our experiments at the moment do not discriminate whether the
phenotypes observed in mutant mice result from decreased STIP1co-
chaperone function, diminished STIP1 extracellular signaling or both.
Our results suggest that reduced levels of STIP1 have important
consequences for behavior and seem to affect brain circuits that
regulate attention. It is possible that exposure to STIP1 antibodies
during pregnancy could reduce STIP1 levels, which, based on the
present results, would have important consequences. Future
experiments are required to define potential mechanisms as well as
the consequences of disturbed STIP1 activity in ASD.
MATERIALS AND METHODS
Animals
STI1−/+ and STI1TGA mice were generated as described (Beraldo et al.,
2013). Both mouse lines were in the C57BL/6J background. All
experimental procedures were conducted in compliance with the
Canadian Council of Animal Care guidelines for use and care of animals
and in accordance with approved animal use protocols at the University of
Western Ontario (2008/127). Animals were housed in groups of two or four
per cage. Mice were kept in a temperature-controlled room with a 12/12
light/dark cycle (7 am/7 pm) with food and water provided ad libitum unless
stated otherwise. For behavioral studies, only male mice were used. Mice
were randomized and the experimenter was blind to genotypes. For most of
the behavioral tasks, software-based analyses were used to score mice
performance with minimum human interference.
qPCR and Western blot
For real-time quantitative PCR (qPCR), brain tissues were homogenized in
Trizol and total RNAwas extracted using the Aurum Total RNA kit for fatty
and fibrous tissue (Bio-Rad, Hercules, CA, USA). qPCR were performed as
previously described (Martins-Silva et al., 2011). Primer sequences:
STIP1-F, 5′-GCCAAGAAAGGAGACTACCAG-3′; STIP1-R, 5′-TCATA-
GGTTCGTTTGGCTTCC-3′; HsP90-F, 5′-CCACCCTGCTCTGTACT-
ACT-3′; HsP90-R, 5′-CCAGGGCATCTGAAGCATTA-3′; HsP70-R,
5′-ACCTTGACAGTAATCGGTGC-3′; HsP70-F, 5′-CTCCCGGTGTGG-
TCTAGAAA-3′; PRP-F, 5′-GAACCATTTCAACCGAGCTG-3′; PRP-R,
5′-CATAGTCACAAAGAGGGCCAG-3′; Actin-F, 5′-TGGAATCCTGT-
GGCATCCATGA-3′; and Actin-R, 5′-AATGCCTGGGTACATGGTGG-
TA-3′. Immunoblot analysis was carried out as described previously
(Beraldo et al., 2013). The antibodies used were anti-STIP1 (1:5000, in-
house antibody generated by Bethyl Laboratories Montgomery, USA using
recombinant STIP1) (Beraldo et al., 2013), anti-Hsp90 (1:1000), anti-Hsp70
(1:1000), anti-Hsp90α (1:1000), anti Hsp90β (1:1000) (Cell Signaling,
Danvers, USA) and anti-PrP 8H4 (1:2000) (Abcam, Cambrige, UK).
Locomotor activity
Mice were acclimated to the testing room for 30 min prior to beginning the
test; locomotor activity was automatically recorded (Omnitech Electronics
Inc., Columbus, USA). Mice were placed in the center of the apparatus and
locomotor activity was measured at 5 min intervals for 1 h as described
previously (Martyn et al., 2012).
Elevated plus maze
To access anxiety-like behavior, mice were acclimated to the testing room
for 30 min prior to beginning the test and then placed in the center of the
Fig. 4. Anxiety-like behavior, depression-like behavior, social
behavior and compulsivity in STI1TGA and STI1−/+ mice.
(A) Percentage of time spent in the closed arm for STI1TGA (n=17)
and control mice (n=14). (B) Percentage of time spent in the open
arm for STI1TGA (n=17) and control mice (n=14). (C) Percentage
of time spent in the closed arm for STI1−/+ (n=13) and control
mice (n=10). (D) Percentage of time spent in the open arm for
STI1−/+ (n=13) and control mice (n=10). (E) Immobility time in the
forced-swimming test for STI1TGA (n=17) and control mice
(n=14). (F) Immobility time in the forced-swimming test forSTI1−/+
(n=6) and control mice (n=8). (G,H) Time spent grooming and
number of grooming bouts for STI1−/+ (n=11) and control mice
(n=11). (I) Marbles buried by STI1−/+ (n=12) and control mice
(n=12).
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elevated plus maze (Med Associates Inc., St Albans, USA). The activity was
recorded and videos were analyzed using ANY-maze software (Stoelting
Co., USA) to determine the amount of time spent in the closed and open
sections of the maze.
Forced swimming test
Depressive-like behavior was assessed by a forced swim test (FST) as
described previously (Martyn et al., 2012). Briefly, mice were placed in a 2 l
beaker containing 1.7 l of water at 25-27°C for 6 min. Experimental sessions
were recorded and immobility time was evaluated using ANY-Maze
Software (Stoelting Co., USA). Data obtained from the last 4 min of testing
were used for the analysis.
Morris water maze
The spatial version of Morris water maze (MWM) was conducted as
described previously (Kolisnyk et al., 2013; Martyn et al., 2012; Vorhees and
Williams, 2006). Briefly, the task was performed in a 1.5-m diameter/1-m
deep pool filled with water at 25°C. Spatial cues, 40×40 cm boards containing
black symbols (vertical and horizontal stripes, triangles, squares and circles),
were placed on the walls distributed around the pool and the platform was
submerged 1 cm below the surface of the water. Mice were submitted to four
training trials a day (90 s each) for four consecutive days with a 15 min
intertrial interval. On day 5, memory was assessed by a single 60 s trial on
which the platform was removed and the time spent in the target quadrant was
evaluated.All the experimental sessionswere recorded and analyzed using the
ANY-Maze Software.
Five-choice serial reaction time task
The five-choice serial reaction time task (5-CSRTT) was used to
evaluate attention in mice as described previously (Kolisnyk et al., 2013;
Romberg et al., 2011). Mice were trained in the 5-CSRTT in automated
Bussey–SaksidaTouch screen systems (Campden Instruments Limited,
Loughborough, EN) and the data collected using ABET II Touch software
V.2.18 (Lafayette Instruments, Lafayette, USA). Mice were submitted to a
pre-training program, which consisted of first habituating the mouse to the
testing chamber with the lights off for 10 min. The next day, the mouse was
Fig. 5. Spatial memory in STI1TGA and STI1−/+ mice. For
the tests, n=14 STI1+/+ and 14 STI1TGA mice were used to
test spatial memory in STI1TGA mice and n=11 STI1+/+ and
11 STI1−/+ for STI1−/+ mice. (A) Latency to find the platform.
(B) Distance traveled. (C) Speed for STI1TGA mice.
(D) Percentage time spent by STI1TGA mice and controls in
target quadrant (T) and in opposite (O), right (R) and left (L)
quadrants was measured on day 5 in a 60 s probe trial with
the platform removed. (E) Latency to find the platform.
(F) Distance traveled. (G) Speed for STI1−/+ mice.
(H) Percentage time spent by STI1−/+ mice and controls in
each quadrant was measured on day 5 in a 60 s probe
trial with the platform removed. Results are presented as
means±s.e.m.; data were analyzed and compared by
two-way ANOVA; ***P<0.001 and ****P<0.0001 compared
with time spent in target quadrant.
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put in the chamber with the lights off for 20 min. After two days of
habituation with no reward been offered, the reward tray was primed with
11% fat strawberry milkshake (Nielson - Saputo Dairy Products) and a tone
was played when themouse entered the reward tray. This was repeated for the
next 2 days for 40 min sessions. Whenever the mouse returned to the reward
tray, the reward was offered and paired with a tone (phase I). The following
training phase consisted in pairing the reward with the presentation of a
random stimulus (flash of light in one of the five windows), which is
removed after 30 s. At this phase, if the mouse touched the screen when the
stimulus was displayed, it received a reward. This cyclewas repeated until the
mouse completed 30 trials or 60 min timeout (phase II). At phase III of the
training, the stimulus was displayed randomly in one of the five windows.
The mouse had to touch the window where the stimulus was displayed to
receive the reward paired with a tone. Similar to phase II, this cycle was
repeated until themouse completed 30 trials or 60 min timeout. The next step
(phase IV) was identical to phase III except by the fact that the mouse had to
poke its nose into the reward trail to initiate the task. This process was
repeated in the last phase of the pre-training (phase V); however, if themouse
touched an incorrect screen, it received a 5 s timeout and the light in the
chamber was turned on. After the mouse had finished pre-training and
reached criterion at 4 s and 2 s stimulus duration (80% accuracy, 20%
omission for three consecutive days), mice were probed for attention deficits
following probe trial schedules: each mouse was tested over two sessions at
1.5, 1.0, 0.8 and 0.6 s stimulus duration (the order of the probe trial sessions
was randomized and the groups counterbalanced). Between each different
stimulus duration, each mouse was returned to a 2 s stimulus for two
consecutive sessions. Number of trials to criterion, accuracy, omission,
reward collection latency and perseverative response were analyzed.
Metabolic assessments
Oxygen consumption, carbon dioxide production, respiratory exchange
ratio (RER), carbon dioxide production, water and food intake and physical
activity were simultaneously measured for adult STI1+/+ and STI1+/− mice
by using the Comprehensive Lab Animal Monitoring System (CLAMS)
interfaced with Oxymax Software (Columbus Instruments, Columbus, OH,
USA) as previously described in detail (Guzman et al., 2013; Kolisnyk et al.,
Fig. 6. Five-choice serial reaction time task used tomeasure attention inSTI1TGA andSTI1−/+. For the tests, n=10STI1+/+ and 10STI1TGAmicewere used to
test attention in STI1TGA mice and n=13 STI1+/+ and 13 STI1−/+ for STI1−/+ mice. (A) Accuracy during probe trial sessions. (B) Rate of omission. (C) Premature
responses. (D) Response latency. (E) Reward collection latency. (F) Perseverative responses for STI1TGA mice. (G) Accuracy during probe trial sessions.
(H) Rate of omission. (I) Premature responses. (J) Response latency. (K) Reward collection latency. (L) Perseverative response for STI1−/+ mice. Results are
presented as means±s.e.m.; data were analyzed and compared by RM-ANOVA; *P<0.05, **P<0.001 compared with control.
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2013). Briefly, mice were individually housed in the metabolic chambers
with ad libitum access to water and food. Following a 16-h habituation
period, all measurements were obtained every 10 min for 24 h (12 h light/
12 h dark).
Marble burying task
A marble burying task was used to assess repetitive and anxiety-like
behavior as previously described (Deacon, 2006).
Assessment of self-grooming
Self-grooming was assessed to evaluate repetitive behavior, as previously
described (McFarlane et al., 2008). Briefly, each mouse was placed
individually in a clean, empty, cage and given a 10 min habituation period,
after which the mice were filmed for another 10 min. Cumulative time spent
grooming and number of grooming bouts were counted by an experimenter
blinded to the genotypes of the mice.
Statistical analyses
Data are presented as mean±s.e.m. Statistical analyses were performed using
SigmaStat 3.5 software. Student’s t-test was used to compare two
experimental groups and for comparison of several experimental groups,
two-way ANOVA or two-way repeated-measures ANOVA were used as
required. Tukey’s post hoc comparison was used when required.
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